Drug Trial Radar · NCT01227824
A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily
Last checked: Nov 19, 2026Latest source record: Oct 9, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
828
Actual
Start
Oct 19, 2010
Primary completion
Feb 6, 2012
Study completion Dec 27, 2016
Sponsor
- Lead sponsor
- ViiV HealthcareGSK (GSK)
- Sponsor type
- Industry
- Collaborators
- Shionogi; GlaxoSmithKline
- First posted
- Oct 25, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this trial is to assess the non-inferior antiviral activity of GSK1349572 50 mg once daily versus RAL 400mg twice daily over 48 weeks; non-inferiority will also be tested at Week 96. Both GSK1349572 and RAL will be given in combination with fixed-dose dual NRTI therapy (ABC/3TC or TDF/FTC). This study will be conducted in HIV-1 infected ART-naïve adult subjects.
Conditions
- Infection, Human Immunodeficiency Virus I
Interventions
GSK1349572 (dolutegravir)Drug
GSK1349572 50 mg taken once daily with or without food
raltegravirDrug
raltegravir 400mg taken twice daily
GSK1349572 PlaceboOther
GSK1349572 placebo taken once daily
ABC/3TCOther
Abacavir/Lamivudine background therapy once daily
TDF/FTCOther
Tenofovir/emtricitabine background therapy once daily
raltegravir PlaceboOther
raltegravir placebo taken twice daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) [HIV-1RNA] <50 Copies (c)/Milliliter (mL) Through Week 48Time frame: Baseline up to Week 48
Locations
101 sites in 9 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Little Rock, Arkansas
GSK Investigational Site
Long Beach, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Los Angeles, California
GSK Investigational Site
Torrance, California
GSK Investigational Site
Denver, Colorado
GSK Investigational Site
Washington D.C., District of Columbia
GSK Investigational Site
Fort Lauderdale, Florida
GSK Investigational Site
Ft. Pierce, Florida
GSK Investigational Site
Atlanta, Georgia
GSK Investigational Site
St Louis, Missouri
GSK Investigational Site
Hillsborough, New Jersey
GSK Investigational Site
Charlotte, North Carolina
GSK Investigational Site
Columbia, South Carolina
GSK Investigational Site
Austin, Texas
GSK Investigational Site
Dallas, Texas
GSK Investigational Site
Houston, Texas
GSK Investigational Site
Houston, Texas
GSK Investigational Site
Seattle, Washington
GSK Investigational Site
Darlinghurst, New South Wales, Australia
GSK Investigational Site
Surry Hills, New South Wales, Australia
GSK Investigational Site
Melbourne, Victoria, Australia
GSK Investigational Site
Vancouver, British Columbia, Canada
GSK Investigational Site
Hamilton, Ontario, Canada
GSK Investigational Site
Ottawa, Ontario, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Toronto, Ontario, Canada
GSK Investigational Site
Montreal, Quebec, Canada
GSK Investigational Site
Montreal, Quebec, Canada
GSK Investigational Site
Garches, France
GSK Investigational Site
Le Kremlin-Bicêtre, France
GSK Investigational Site
Levallois-Perret, France
GSK Investigational Site
Lyon, France
GSK Investigational Site
Marseille, France
GSK Investigational Site
Nantes, France
GSK Investigational Site
Paris, France
GSK Investigational Site
Paris, France
GSK Investigational Site
Paris, France
GSK Investigational Site
Paris, France
Showing 40 of 101 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.